Literature DB >> 31772978

Dosimetric Comparison of Plans for Photon- or Proton-Beam Based Radiosurgery of Liver Metastases.

Gracinda Mondlane1,2, Michael Gubanski3, Pehr A Lind3,4, Thomas Henry1, Ana Ureba1, Albert Siegbahn1.   

Abstract

PURPOSE: Radiosurgery treatment of liver metastases with photon beams has been an established method for more than a decade. One method commonly used is the stereotactic body radiation therapy (SBRT) technique. The aim of this study was to investigate the potential sparing of the organs at risk (OARs) that the use of intensity-modulated proton therapy (IMPT), instead of SBRT, could enable. PATIENTS AND METHODS: A comparative treatment-planning study of photon-beam and proton-beam based liver-cancer radiosurgery was performed. Ten patients diagnosed with liver metastasis and previously treated with SBRT at the Karolinska University Hospital were included in the study. New IMPT plans were prepared for all patients, while the original plans were set as reference plans. The IMPT planning was performed with the objective of achieving the same target dose coverage as with the SBRT plans. Pairwise dosimetric comparisons of the treatment plans were then performed for the OARs. A 2-sided Wilcoxon signed-rank test with significance level of 5% was carried out.
RESULTS: Improved sparing of the OARs was made possible with the IMPT plans. There was a significant decrease of the mean doses delivered to the following risk organs: the nontargeted part of the liver (P = .002), the esophagus (P = .002), the right kidney (P = .008), the spinal cord (P = .004), and the lungs (P = .002). The volume of the liver receiving less than 15 Gy was significantly increased with the IMPT plans (P = .004).
CONCLUSION: The IMPT-based radiosurgery plans provided similar target coverage and significant dose reductions for the OARs compared with the photon-beam based SBRT plans. Further studies including detailed information about varying tissue heterogeneities in the beam path, due to organ motion, are required to evaluate more accurately whether IMPT is preferable for the radiosurgical treatment of liver metastases. © Copyright 2016 International Journal of Particle Therapy.

Entities:  

Keywords:  intensity-modulated proton therapy; liver metastases; stereotactic body radiation therapy; treatment planning

Year:  2016        PMID: 31772978      PMCID: PMC6871612          DOI: 10.14338/IJPT-16-00010.1

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN: 2331-5180


  19 in total

1.  Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma.

Authors:  Shohei Komatsu; Takumi Fukumoto; Yusuke Demizu; Daisuke Miyawaki; Kazuki Terashima; Ryohei Sasaki; Yuichi Hori; Yoshio Hishikawa; Yonson Ku; Masao Murakami
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

Review 2.  Treatment modalities for hepatocellular carcinoma.

Authors:  Huynh Hung
Journal:  Curr Cancer Drug Targets       Date:  2005-03       Impact factor: 3.428

3.  Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities.

Authors:  Ke-Tong Wu; Cun-Chuan Wang; Li-Gong Lu; Wei-Dong Zhang; Fu-Jun Zhang; Feng Shi; Chuan-Xing Li
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

4.  Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours.

Authors:  Jørgen B B Petersen; Yasmin Lassen; Anders T Hansen; Ludvig P Muren; Cai Grau; Morten Høyer
Journal:  Acta Oncol       Date:  2011-08       Impact factor: 4.089

5.  Carbon-Ion Pencil Beam Scanning Treatment With Gated Markerless Tumor Tracking: An Analysis of Positional Accuracy.

Authors:  Shinichiro Mori; Masataka Karube; Toshiyuki Shirai; Minoru Tajiri; Takuro Takekoshi; Kentaro Miki; Yurika Shiraishi; Katsuyuki Tanimoto; Kouichi Shibayama; Shigeo Yasuda; Naoyoshi Yamamoto; Shigeru Yamada; Hiroshi Tsuji; Koji Noda; Tadashi Kamada
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-01-20       Impact factor: 7.038

6.  Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons.

Authors:  Saumil J Gandhi; Xing Liang; Xuanfeng Ding; Timothy C Zhu; Edgar Ben-Josef; John P Plastaras; James M Metz; Stefan Both; Smith Apisarnthanarax
Journal:  Pract Radiat Oncol       Date:  2015-02-18

7.  Analysis of radiation-induced liver disease using the Lyman NTCP model.

Authors:  Laura A Dawson; Daniel Normolle; James M Balter; Cornelius J McGinn; Theodore S Lawrence; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

8.  Proton beam therapy for large hepatocellular carcinoma.

Authors:  Shinji Sugahara; Yoshiko Oshiro; Hidetsugu Nakayama; Kuniaki Fukuda; Masashi Mizumoto; Masato Abei; Junichi Shoda; Yasushi Matsuzaki; Eriko Thono; Mari Tokita; Koji Tsuboi; Koichi Tokuuye
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-07       Impact factor: 7.038

9.  Particle radiation therapy for gastrointestinal malignancies.

Authors:  Jeffrey J Meyer; Brian G Czito; Christopher G Willett
Journal:  Gastrointest Cancer Res       Date:  2007

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  2 in total

1.  The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation.

Authors:  Luca Cozzi; Tiziana Comito; Mauro Loi; Antonella Fogliata; Ciro Franzese; Davide Franceschini; Elena Clerici; Giacomo Reggiori; Stefano Tomatis; Marta Scorsetti
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 2.  Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases.

Authors:  Paul B Romesser; Neelam Tyagi; Christopher H Crane
Journal:  Cancers (Basel)       Date:  2021-04-01       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.